Evidence map›Paper›PMID 29869023›Full record

ArticleJournal of neuro-oncology2018

The relationship of study and authorship characteristics on trial sponsorship and self-reported conflicts of interest among neuro-oncology clinical trials.

Srinivas Raman, Fabio Y Moraes, Lucas C Mendez, Neil K Taunk, John H Suh, Luis Souhami, Ben Slotman, Paul Kongkham, Daniel E Spratt, Alejandro Berlin and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Srinivas RamanDepartment of Radiation Oncology, University of Toronto/Princess Margaret Hospital, 700 University Avenue, Toronto, ON, M5G 2M9, Canada.
Fabio Y MoraesDepartment of Radiation Oncology, University of Toronto/Princess Margaret Hospital, 700 University Avenue, Toronto, ON, M5G 2M9, Canada. fymoraes@gmail.com.
Lucas C MendezDepartment of Radiation Oncology, University of Toronto/Sunnybrook Odette Cancer Centre, Toronto, ON, Canada.
Neil K TaunkDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.
John H SuhDepartment of Radiation Oncology, Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Taussig Cancer Institute, Cleveland, OH, USA.
Luis SouhamiDepartment of Radiation Oncology, McGill University Health Centre, Montreal, QC, Canada.
Ben SlotmanDepartment of Radiation Oncology, Vrije Universiteit Medical Center (VUmc), Amsterdam, The Netherlands.
Paul KongkhamDepartment of Neursurgery, University of Toronto/Toronto Western Hospital, Toronto, ON, Canada.
Daniel E SprattDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Alejandro BerlinDepartment of Radiation Oncology, University of Toronto/Princess Margaret Hospital, 700 University Avenue, Toronto, ON, M5G 2M9, Canada.
Gustavo N MartaDepartment of Radiation Oncology, Hospital Sírio-Libânes, São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

proposeTo examine the association between trial sponsorship sources, self-reported conflicts of interest (COI), and study and author characteristics in central nervous system (CNS) oncology clinical trials (CT).

methodsMEDLINE search was performed for original CT on "Central Nervous System Neoplasms"[Mesh]. The investigators assessed for relationships between funding source (industry, academic or cooperative, none, not described), COI (presented, none, or not reported), CT, and author characteristics.

resultsFrom 2010 to 2015, 319 CT were considered eligible. The majority of the studies involved primary gliomas (55.2%) and were Phase II CT (59.2%). Drug therapy was investigated in 83.0% of the CT. The remaining studies investigated surgery or radiotherapy. A minority of papers were published in journals with impact factor (IF) higher than > 10 (16%) or in regions other than North America and Europe (20.4%). Overall, 83.1% of studies disclosed funding sources: 32.6% from industry alone, 33.9% from an academic or cooperative group, and 10.7% from a mixed funding model. COI data was reported by 85.9% of trials, of which 56.2% reported no COI and 43.8% reported a related COI. Significant predictors for sponsorship (industry and/or academia) on univariate analysis were study design, type of intervention, journal impact factor, study conclusion, transparency of COI and presence of COI. On multivariate analysis, type of intervention, (P < 0.001), journal impact factor (IF) (P = 0.003), presence of COI (P < 0.001) and study conclusion (P = 0.003) remained significant predictors of sponsorship. For predicting COI, significant variables on univariate analysis were disease type, type of intervention, journal IF, funding source, and intervention arm being related to sponsor. On multivariate analysis, disease type (P = 0.003), journal IF (P < 0.001), type of intervention (P = 0.001), and funding source (P = 0.008) remained significant.

conclusionsThe majority of CNS CT reported some external funding sources and non-related COI. We identified that drug trials, higher IF, presence of COI, and a neutral or negative study conclusion are associated with external funding. Likewise drug trials, higher IF, and glioma trials are associated with presence of COI.

Indexed as

AuthorshipCentral Nervous System NeoplasmsClinical Trials as TopicConflict of InterestHumansMedical OncologyNeurologyResearch PersonnelScholarly CommunicationSelf ReportCentral nervous system NeoplasmConflict of interestGliomaMetastasesOncologyTreatment

Identifiers

PMID29869023

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.